Remed

At a glance

Remed filed 62 disclosures in the last 12 months, including 26 5% holder, 8 buyback, 5 insider and 1 issuance. The most recent key filing was on Oct 30: A major holder's stake rose from 36.88% to 36.88% (pledge).

Revenue for 2025 was ₩24.5B, down 4.1% on 2024. Operating margin was 3% against 4.4% a year earlier. Debt was 37% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩14.5B and operating profit of ₩1.6B.

The 2025 annual report lists 114 employees with an average tenure of 3.5 years and average pay of ₩46.8M, #1592 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩105.8M each on average. It paid no cash dividend for 2025. 이근용 and related parties held 34.90% at year end.

Of 2 recent 5%+ holder reports, 0 raised and 0 cut a stake; the largest stake reported was 36.88% on Oct 30.

From the 2025 annual report

Staff: 114 (81 men, 33 women), of whom 22 on fixed-term contracts. Total pay for the year: ₩4.4B. Directors and auditors: 7, paid ₩657.6M in total.

No cash dividend was paid for 2025.

Largest shareholder

이근용 holds 25.70%; with 3 related parties the group holds 34.90% of common shares at year end (from 36.10% at the start of the year).

Auditor: 도원회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports